(Q38216322)

31 August 2017

title

Endocrine aspects of bone metastases (English)

1 reference

31 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24880565%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Tilman D Rachner

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24880565%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Robert E Coleman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24880565%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Franz Jakob

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24880565%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

24 January 2014

1 reference

The Lancet: Diabetes & Endocrinology

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24880565%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24880565%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24880565%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

500-512

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24880565%20AND%20SRC:MED&resulttype=core&format=json

Effect of three decades of screening mammography on breast-cancer incidence

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Fracture risk with multiple myeloma: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Mechanisms of bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Cancer to bone: a fatal attraction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Osteoporosis: now and the future

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Dickkopf-1: a suitable target for the management of myeloma bone disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Activin receptor antagonists for cancer-related anemia and bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

The amazing osteocyte

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Risk of fracture after androgen deprivation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Estrogen and the skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of Runx2 in skeletal tissues

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Breast cancer and hormone-replacement therapy: the Million Women Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Update in hormone therapy use in menopause

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Prostate cancer and parasitism of the bone hematopoietic stem cell niche

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

National practice patterns and time trends in androgen ablation for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Abiraterone in metastatic prostate cancer without previous chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Testosterone therapy in men with prostate cancer: scientific and ethical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Vitamin D deficiency promotes prostate cancer growth in bone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Estrogenic or antiestrogenic therapies for multiple myeloma?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

17beta-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Genistein down-regulates the constitutive activation of nuclear factor-kappaB in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Effects of dexamethasone, all-trans retinoic acid, vitamin D(3) and interferon-alpha on FO myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Prevalence and significance of vitamin D deficiency in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Vitamin D status may effect the skeletal complications of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Regulation of cancer cell migration and bone metastasis by RANKL.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

The clinical course of bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

ERα, microRNAs, and the epithelial-mesenchymal transition in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

TGF-beta signaling in tumor suppression and cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Sclerostin is overexpressed by plasma cells from multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Myeloma cells suppress osteoblasts through sclerostin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

The activin A-follistatin system: potent regulator of human extracellular matrix mineralization

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Activin A stimulates AKR1C3 expression and growth in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Activin type IB receptor signaling in prostate cancer cells promotes lymph node metastasis in a xenograft model.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Therapeutic targets for bone metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Increased Dickkopf-1 expression in breast cancer bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

The role of Wnts in bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Breast-cancer adjuvant therapy with zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Management of cancer treatment-induced bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Bisphosphonates in multiple myeloma: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Fracture risk in monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970203-1

7 January 2021

10.1016/S2213-8587(13)70203-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24880565%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference